Condition: Oropharyngeal Cancers · HPV · Tonsil Cancer · Sponsor: Georgetown University
The current standard treatment option for Human Papillomavirus (HPV) or p16-positive oropharyngeal cancer is full-dose radiation combined with chemotherapy. Results with chemotherapy combined with full-dose radiation therapy leads to high rates of cure; this has called into question whether therapy can be decreased in intensity since both chemotherapy and radiation have long-term side effects. One approach to decrease intensity of treatment is to give radiation alone (excluding chemotherapy) and to decrease radiation therapy dose. The investigator believes that omitting chemotherapy and decreasing radiation dose both to tumor and the regions of the head and neck at highest risk of potential spread, may have no significant impact on the cancer recurring while potentially leading to fewer long-term side effects.
This description comes directly from the study's public registry record.
Peter H Ahn, MD · 202-444-6385 · peter.h.ahn@gunet.georgetown.edu
Nicole Swanson · ns1209@georgetown.edu
Always discuss trial participation with your own doctor first.
| Medstar Georgetown University Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Medstar Southern Maryland Hospital Center | Clinton, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06902623